Gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are fairly rare neoplasms
that present many clinical challenges. They secrete peptides and neuroamines that cause …

The endocrine tumours of the gastrointestinal tract have been attracting the attention of
clinicians since their very first identification, which paralleled the identification of gut …

ABSTRACT Background Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity
of randomized studies, this expert consensus document represents an initiative by the …

Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …

Background The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against
pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. Methods …

Background Somatostatin analogues are commonly used to treat symptoms associated with
hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects …

Background: The risk of pancreatic cancer in patients with chronic pancreatitis (CP) is
difficult to assess. Previous studies, mostly case control studies or studies relying on data …

Purpose No established treatment exists for pancreatic neuroendocrine tumor (NET)
progression after failure of chemotherapy. Everolimus (RAD001), an oral inhibitor of …

Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …

Purpose The management of locally advanced (LA) pancreatic cancer patients remains
controversial. To select patients who could benefit from chemoradiotherapy (CRT), the …